JoS

Yang et al.   SGLT2i Improves Neurological Outcomes After Stroke

Variable	No SGLT2i	SGLT2i	OR (95% CI) SGLT2i vs. No SGLT2i	p for interaction
Age				0.419
≤65 years	60/111 (54.1%)	22/29 (75.9%)	2.67 (1.06-6.76)	
>65 years	66/148 (44.6%)	24/42 (57.1%)	1.66 (0.83-3.31)	
Sex				0.498
Male	86/171 (50.3%)	32/46 (69.6%)	2.26 (1.13-4.53)	
Female	40/88 (45.5%)	14/25 (56.0%)	1.53 (0.62-3.73)	
HbA1c				0.563
<7.0%	33/67 (49.3%)	10/17 (58.8%)	1.47 (0.50-4.33)	
≥7.0%	93/192 (48.4%)	36/54 (66.7%)	2.13 (1.13-4.01)	
eGFR				0.387
≥60	100/191 (52.4%)	33/52 (63.5%)	1.58 (0.84-2.97)	
30-59	23/58 (39.7%)	12/16 (75.0%)	4.57 (1.31-15.90)	
15-29	3/10 (30.0%)	1/3 (33.3%)	1.17 (0.07-18.35)	
ICAS				0.846
Yes	59/130 (45.4%)	24/38 (63.2%)	2.06 (0.98-4.34)	
No	67/129 (51.9%)	22/33 (66.7%)	1.85 (0.83-4.13)	
Total SVD score				0.393
0-2	87/149 (58.4%)	29/42 (69.0%)	1.59 (0.77-3.30)	
3-4	39/110 (35.5%)	17/29 (58.6%)	2.58 (1.12-5.95)	
Initial NIHSS				0.686
0-4	102/173 (59.0%)	36/51 (70.6%)	1.67 (0.85-3.28)	
5-15	23/72 (31.9%)	10/16 (62.5%)	3.55 (1.15-10.96)	
≥16	1/14 (7.1%)	0/4 (0.0%)	–	
Stroke etiology				0.940
LAA	56/120 (46.7%)	23/34 (67.6%)	2.39 (1.07-5.33)	
SVO	33/61 (54.1%)	9/15 (60.0%)	1.27 (0.40-4.02)	
CE	25/50 (50.0%)	8/14 (57.1%)	1.33 (0.40-4.40)	
Others	12/28 (42.9%)	6/8 (75.0%)	4.00 (0.68-23.41)	
END				0.458
Yes	1/30 (3.3%)	1/6 (16.7%)	5.80 (0.31-108.48)	
No	125/229 (54.6%)	45/65 (69.2%)	1.87 (1.04-3.37)	

1.0   2.0   4.0   8.00

Supplementary Figure 3. Odds of excellent outcome at 3 months stratified by clinical factors. Forest plot illustrating the ORs and 95% CIs for the association between SGLT2i use and 3-month excellent outcome. The strata included age, sex, glycemic control, renal function, intracranial atherosclerosis, total SVD score, neurological severity, stroke etiology, and END. ORs were calculated from binary logistic regression analysis with multiplicative interaction terms on propensity score-matched data and plotted on the x-axis on a log scale. SGLT2i, sodium-glucose cotransporter 2 inhibitor; OR, odds ratio; CI, confidence interval; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; ICAS, intracranial atherosclerosis; SVD, small vessel disease; NIHSS, National Institutes of Health Stroke Scale; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; END, early neurological deterioration.